Real-world performance of plasma p-tau181 in a heterogeneous memory clinic cohort.
Tandis ParviziRaphael WurmTheresa KönigSara SilvaiehPatrick AltmannSigrid KlotzGuenther RegelsbergerTatjana Traub-WeidingerEllen GelpíElisabeth StögmannPublished in: Annals of clinical and translational neurology (2024)
Our findings demonstrate that plasma p-tau181 could be a noninvasive and feasible prescreening marker for amyloid positivity in a heterogeneous clinical AD cohort and therefore help in identifying those who would benefit from more invasive assessment of amyloid pathology.